Denosumab Therapy Duration and Osteonecrosis of the Jaw and Skeletal Events in Bone-Metastatic Prostate Cancer
JAMA Network Open · 21.10.2026 · 9 (10) · e2639765
DOI: 10.1001/jamanetworkopen.2026.39765 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 21.10.2026. Verfasst von Seoree Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Hemato-oncology, Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University of Korea, Bucheon, Republic…. Hauptthemen laut MEDLINE: Denosumab, Bone Neoplasms, Bone Density Conservation Agents, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Importance Denosumab reduces skeletal-related events in bone-metastatic prostate cancer but carries a cumulative risk of medication-related osteonecrosis of the jaw (ONJ). The treatment duration that best balances these risks has not been established in clinical settings.
Objective
To evaluate the association between duration of denosumab treatment and the 3-year cumulative incidence of ONJ and skeletal events. Design, Setting, and Participants This nationwide retrospective cohort study emulated a target trial using Korean Health Insurance Review and Assessment Service data from January 1, 2009, through August 31, 2024; patients were not randomized. A clone-censor-weight approach with inverse probability of censoring weighting estimated 3-year cumulative incidence and risk ratios (RRs), with death as a competing event. Men included in the analysis had bone-metastatic castration-resistant prostate cancer and initiated oncologic-dose denosumab therapy; men with castration-sensitive disease were excluded. Exposures Six strategies defined by 3 durations (≤6, 7-12, and ≥13 months), each as a schedule-flexible group and a schedule-adherent subgroup (intervals ≤12 weeks). Main Outcomes and Measures Three-year cumulative incidence of ONJ and skeletal events (pathologic fracture, spinal cord compression, and surgery to bone) was the primary outcome; a radiotherapy-inclusive conventional composite of skeletal-related events was assessed as a secondary outcome.
Results
Among 3307 men included in the analysis (mean [SD] age, 72.6 [8.6] years; median follow-up, 42.6 [IQR, 26.5-57.4] months), the overall 3-year cumulative incidence was 9.8% (95% CI, 8.7%-11.0%) for ONJ and 4.9% (95% CI, 4.2%-5.7%) for skeletal events. Relative to treatment for 6 months or less, treatment for 7 to 12 months showed a lower risk of skeletal events (3.82% [95% CI, 3.04%-4.80%] vs 5.76% [95% CI, 4.23%-7.79%]; RR, 0.66 [95% CI, 0.45-0.97]) and higher risk of ONJ (3.28% [95% CI, 2.41%-4.44%] vs 1.47% [95% CI, 0.86%-2.50%]; RR, 2.22 [95% CI, 1.21-4.11]). Compared with 7 to 12 months, treatment for 13 months or longer was associated with higher risk of ONJ (12.20% [95% CI, 10.86%-13.68%]; risk difference, 8.93 [95% CI, 7.16-10.64] percentage points), without further reduction in risk for skeletal events (3.99% [95% CI, 3.30%-4.82%]; risk difference, 0.17 [95% CI, −1.03 to 1.31] percentage points). Conclusions and Relevance In this cohort study of bone-metastatic castration-resistant prostate cancer, denosumab treatment for 7 to 12 months was associated with lower risk of skeletal events and a modest increase in ONJ, whereas treatment beyond 12 months was associated with markedly higher ONJ risk but no further reduction of skeletal events. These findings support individualized reassessment of denosumab treatment duration after approximately 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Hemato-oncology, Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University of Korea, Bucheon, Republic of Korea.
- Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Data Science, PIPET (Pharmacometrics Institute for Practical Education and Training), The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Kim, S., Jung, S., Bu, S., Kim, J. W., Pyo, S. W., Lee, G. J., Chun, S. H., Kim, I. H., Park, S. S., & Choi, S. (2026). Denosumab Therapy Duration and Osteonecrosis of the Jaw and Skeletal Events in Bone-Metastatic Prostate Cancer. JAMA Network Open, 9(10), e2639765. https://doi.org/10.1001/jamanetworkopen.2026.39765
Vancouver
Kim S, Jung S, Bu S, Kim JW, Pyo SW, Lee GJ, et al. Denosumab Therapy Duration and Osteonecrosis of the Jaw and Skeletal Events in Bone-Metastatic Prostate Cancer. JAMA Network Open. 2026;9(10):e2639765. doi:10.1001/jamanetworkopen.2026.39765
BibTeX
@article{Kim2026,
author = {Kim, Seoree and Jung, Seungpil and Bu, Seonghyeon and Kim, Jin Woo and Pyo, Sung Woon and Lee, Guk Jin and Chun, Sang Hoon and Kim, In-Ho and Park, Sung-Soo and Choi, Suein},
title = {Denosumab Therapy Duration and Osteonecrosis of the Jaw and Skeletal Events in Bone-Metastatic Prostate Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {10},
pages = {e2639765},
doi = {10.1001/jamanetworkopen.2026.39765}
}
EUVIMED